Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechSci Research | PRODUCT CODE: 1878856

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1878856

EV-Based Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offering, By Workflow, By Technology, By Sample Type, By End user, By Region and Competition, 2020-2030F

PUBLISHED:
PAGES: 185 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4500
PDF and Excel (Multi-User License)
USD 5500
PDF and Excel (Custom Research License)
USD 8000

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

The Global EV-Based Liquid Biopsy Market , valued at USD 91.12 Million in 2024, is projected to experience a CAGR of 9.74% to reach USD 159.14 Million by 2030. Extracellular vesicle (EV)-based liquid biopsy involves the non-invasive analysis of disease-specific biomarkers encapsulated within extracellular vesicles, such as exosomes, circulating in bodily fluids like blood or urine. These vesicles carry molecular cargoes including proteins, nucleic acids, and lipids, providing insights into the physiological and pathological state of originating cells. The market's expansion is significantly driven by the increasing global burden of chronic diseases, particularly cancer, and the rising demand for early, non-invasive diagnostic solutions. The inherent stability and abundance of EVs in biofluids, offering advantages over other circulating biomarkers, also act as key growth facilitators.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 91.12 Million
Market Size 2030USD 159.14 Million
CAGR 2025-20309.74%
Fastest Growing SegmentKits & Assays
Largest MarketNorth America

Key Market Drivers

The escalating global cancer burden fundamentally drives the EV-based liquid biopsy market. Traditional diagnostic methods often face limitations in early detection and continuous monitoring, areas where the non-invasive nature of EV liquid biopsies offers significant advantages. As cancer incidence continues its upward trajectory, the urgency for advanced, accessible diagnostic tools intensifies. According to the International Agency for Research on Cancer (IARC), in 2022, there were close to 20 million new cases of cancer worldwide. This pervasive health crisis necessitates innovative solutions that can accurately identify malignancies at earlier stages and monitor treatment efficacy without the invasiveness of tissue biopsies, directly propelling the adoption and development of EV-based platforms.

Key Market Challenges

A substantial challenge impeding the growth of the Global EV-Based Liquid Biopsy Market is the ongoing technical complexity associated with isolating and comprehensively characterizing extracellular vesicles (EVs) from complex biofluids. This inherent variability in isolation methods and subsequent characterization protocols often leads to significant issues with reproducibility and consistent clinical validation. The lack of standardized procedures across different laboratories and platforms directly compromises the reliability of test results, creating skepticism among clinicians and delaying the widespread adoption of EV-based diagnostic solutions.

Key Market Trends

The emergence of novel EV biomarkers is significantly shaping the global EV-based liquid biopsy market by enhancing diagnostic precision and expanding application areas. Research into disease-specific cargo within extracellular vesicles, such as proteins and nucleic acids, is uncovering new targets for early detection and disease monitoring across various pathologies. This focus on biomarker discovery drives the development of more sensitive and specific diagnostic assays. According to the International Society for Extracellular Vesicles, its MISEV2023 guidelines, published in March 2024, garnered consensus from approximately 97% of surveyed members, reflecting a widespread scientific commitment to standardizing and advancing EV research which underpins biomarker identification. This collective effort is crucial for translating promising biomarker candidates into validated clinical tools. Furthermore, a review article in *Biology (Basel)* in September 2024, highlighted the therapeutic opportunity of tumor-derived extracellular vesicles, emphasizing their capacity to harbor cancer-derived cargo reflective of their cell-of-origin and their superior stability in blood for diagnostic and prognostic insights.

Key Market Players

  • Horiba Ltd.
  • Thermo Fisher Scientific, Inc.
  • Lonza Group AG
  • Takara Bio Inc.
  • Abcam plc
  • Qiagen N.V.
  • Malvern Panalytical Ltd.
  • Revvity, Inc. (PerkinElmer, Inc)
  • Norgen Biotek Corp.
  • Bio-Techne Corporation

Report Scope:

In this report, the Global EV-Based Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

EV-Based Liquid Biopsy Market , By Offering:

  • Kits & Assays
  • Services
  • Instruments

EV-Based Liquid Biopsy Market , By Workflow:

  • Sample Preparation
  • Sequencing
  • Data Analysis

EV-Based Liquid Biopsy Market , By Technology:

  • Isolation Technologies
  • Analysis Technologies

EV-Based Liquid Biopsy Market , By Sample Type:

  • Blood
  • Urine
  • Saliva
  • Others

EV-Based Liquid Biopsy Market , By End User:

  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Clinical Laboratories

EV-Based Liquid Biopsy Market , By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global EV-Based Liquid Biopsy Market .

Available Customizations:

Global EV-Based Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Product Code: 15834

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global EV-Based Liquid Biopsy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Offering (Kits & Assays, Services, Instruments)
    • 5.2.2. By Workflow (Sample Preparation, Sequencing, Data Analysis)
    • 5.2.3. By Technology (Isolation Technologies, Analysis Technologies)
    • 5.2.4. By Sample Type (Blood, Urine, Saliva, Others)
    • 5.2.5. By End User (Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Clinical Laboratories)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map

6. North America EV-Based Liquid Biopsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Offering
    • 6.2.2. By Workflow
    • 6.2.3. By Technology
    • 6.2.4. By Sample Type
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States EV-Based Liquid Biopsy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Offering
        • 6.3.1.2.2. By Workflow
        • 6.3.1.2.3. By Technology
        • 6.3.1.2.4. By Sample Type
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada EV-Based Liquid Biopsy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Offering
        • 6.3.2.2.2. By Workflow
        • 6.3.2.2.3. By Technology
        • 6.3.2.2.4. By Sample Type
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico EV-Based Liquid Biopsy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Offering
        • 6.3.3.2.2. By Workflow
        • 6.3.3.2.3. By Technology
        • 6.3.3.2.4. By Sample Type
        • 6.3.3.2.5. By End User

7. Europe EV-Based Liquid Biopsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Offering
    • 7.2.2. By Workflow
    • 7.2.3. By Technology
    • 7.2.4. By Sample Type
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany EV-Based Liquid Biopsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Offering
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By Sample Type
        • 7.3.1.2.5. By End User
    • 7.3.2. France EV-Based Liquid Biopsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Offering
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By Sample Type
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom EV-Based Liquid Biopsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Offering
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By Sample Type
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy EV-Based Liquid Biopsy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Offering
        • 7.3.4.2.2. By Workflow
        • 7.3.4.2.3. By Technology
        • 7.3.4.2.4. By Sample Type
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain EV-Based Liquid Biopsy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Offering
        • 7.3.5.2.2. By Workflow
        • 7.3.5.2.3. By Technology
        • 7.3.5.2.4. By Sample Type
        • 7.3.5.2.5. By End User

8. Asia Pacific EV-Based Liquid Biopsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Offering
    • 8.2.2. By Workflow
    • 8.2.3. By Technology
    • 8.2.4. By Sample Type
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China EV-Based Liquid Biopsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Offering
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Sample Type
        • 8.3.1.2.5. By End User
    • 8.3.2. India EV-Based Liquid Biopsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Offering
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Sample Type
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan EV-Based Liquid Biopsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Offering
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Sample Type
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea EV-Based Liquid Biopsy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Offering
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By Sample Type
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia EV-Based Liquid Biopsy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Offering
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By Sample Type
        • 8.3.5.2.5. By End User

9. Middle East & Africa EV-Based Liquid Biopsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Offering
    • 9.2.2. By Workflow
    • 9.2.3. By Technology
    • 9.2.4. By Sample Type
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia EV-Based Liquid Biopsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Offering
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Sample Type
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE EV-Based Liquid Biopsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Offering
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Sample Type
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa EV-Based Liquid Biopsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Offering
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Sample Type
        • 9.3.3.2.5. By End User

10. South America EV-Based Liquid Biopsy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Offering
    • 10.2.2. By Workflow
    • 10.2.3. By Technology
    • 10.2.4. By Sample Type
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil EV-Based Liquid Biopsy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Offering
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Sample Type
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia EV-Based Liquid Biopsy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Offering
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Sample Type
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina EV-Based Liquid Biopsy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Offering
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Sample Type
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global EV-Based Liquid Biopsy Market : SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Horiba Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific, Inc.
  • 15.3. Lonza Group AG
  • 15.4. Takara Bio Inc.
  • 15.5. Abcam plc
  • 15.6. Qiagen N.V.
  • 15.7. Malvern Panalytical Ltd.
  • 15.8. Revvity, Inc. (PerkinElmer, Inc)
  • 15.9. Norgen Biotek Corp.
  • 15.10. Bio-Techne Corporation

16. Strategic Recommendations

17. About Us & Disclaimer

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!